Nasdaq Past Champ (STSS) Has Breaking News Out Today (5 Key Potential Catalysts)

The market is open so there's zero time to waste. Nasdaq Past Champ (STSS) Has Breaking News Out Today (5 Key Potential Catalysts) January 31st Dear Reader, The market is open so there's zero time to waste. Previously brought to your attention back towards the beginning of this month, this Nasdaq past champ needs to get back on your radar immediately. Alerted for the morning of the 11th, this profile popped approximately 29% in the span of two days. Even better, this company could be on the cusp of something monumental as they look to disrupt the [global market]( for smart syringes which is estimated to be approximately $7.0Bn in 2023 and is projected to increase to $11Bn by 2030. On top of that, their lead product, a "world's first," could start the revenue train in 2023. Plus, the company made this [major announcement today.]( Factor in those details along with Yahoo Finance reporting this profile to have fewer than 6Mn shares in its float, and you can see why time could be of the essence on this one. Drop everything and get this under-the-radar breakout idea pulled up now: *Sharps Technology, Inc. (STSS)* Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. And right now, STSS has several potential catalysts to familiarize yourself with immediately. Check them out: No. 1 - A Low Float Could Provide Significant Potential For Explosive Volatility No. 2 - 2023 Could Be A HUGE Year For Sharps (New Product Launch Nears) No. 3 - With Manufacturing Ramping Up, Revenue Should Be Getting Even Closer No. 4 - New Distro Agreement Signed, 2023 Continues To Look Brighter And Brighter No. 5 - Joining The Nasdaq Capital Market In 2022 Opened Sharps To All Kinds Of New Exposure But more on those in a second... Injections Should Not Cause Infections The Problem With healthcare workers delivering more than 16Bn injections a year worldwide, the risk of accidental needlestick injuries and exposure to dangerous bloodborne pathogens is real and urgent. In fact, the World Health Organization (WHO) has named needlestick injuries “one of the greatest risks faced by the frontline healthcare worker.” The U.S. Centers for Disease Control and Prevention (CDC) even made eliminating them a national priority, pushing for the healthcare industry to fully adopt safety syringes by 2020—a goal which has not been reached. Why not? One explanation: Virtually every safety syringe introduced so far has required the user to activate hinges, slides, or springs to engage their safety mechanisms. Lack of standardized design, their complexity, and practice changes are barriers to compliance, and may even be contributing to the problem. Nearly 40% of needle injuries involve a safety needle—the vast majority because users did not activate the safety features. The other 60% involve traditional syringes with no safety features at all. Needlesticks disrupt the lives of at least half a million healthcare personnel each and every year, often with devastating results, including infections, psychological trauma, destroyed careers, and financial ruin. The Solution Sharps Technology offers a solution to this global healthcare crisis. Sharps Provensa smart safety syringes are the first of their kind designed to eliminate two million potentially infectious accidental needlestick injuries, as well as $Bn's in medicine wasted with today’s inefficient syringes. Sharps Provensa™ syringes are addressing the important needs of the global healthcare market: - Provides automatic protection from accidental needlestick injection for clinicians and all who come in contact with contaminated needles. - Prevents improper reuse of both needle and syringe by automatically locking the plunger and shielded needle following injection. - Ultra Low-Waste™ dramatically reduces the amount of costly medications discarded with inefficient injections. For the first time ever, needlesticks can be completely avoided, easing the financial burden on the healthcare system and giving clinical staff and the general public total protection and true peace of mind. Sharps Provensa™ is the company's premier line of smart safety syringes that offer solutions to global healthcare crises. Their Ultra-Low Waste™ syringes offer a solution to minimize vaccine waste while offering reliable needlestick protection. The Sharps Provensa™ needle tip goes through the skin sharp, delivering the medicine or vaccine, and comes out of the body shielded, protecting the healthcare worker and the public. Sharps Technology syringes are patented and comply with US regulatory and WHO guidelines. Their safety syringes are currently being produced at the company's ISO certified, FDA-cleared facility for medical device production with CE mark approval. [Grab more key company details here.]( ----- And as I mentioned previously, STSS has multiple potential catalysts to know now. Here they are: No. 1 STSS Potential Catalyst - A Low Float Could Provide Significant Potential For Explosive Volatility According to the [Yahoo Finance]( website, STSS has a low float. The website reports this profile to have approximately 5.6Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive company news early in 2023 provide a near term spark? ----- No. 2 STSS Potential Catalyst - 2023 Could Be A HUGE Year For Sharps (New Product Launch Nears) Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023 High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based syringe products for the healthcare market NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina. Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems. These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors. The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market." Sharps' specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment. Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+Mn units, with additional capacities that can be scaled by 2025 with an additional 100Mn units annually. Products will be manufactured utilizing state-of-the-art Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps' PFS systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry. Robert Hayes, Sharps Chief Executive Officer, commented: "Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opp. to advance our product and manufacturing strategy to include high value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond. The launch of these products could not come at a better time to support a market that is in demand for products produced in the USA that provide specialized solutions for customers that need optionality for their drug filling operations. We look forward to providing updates as we commence manufacturing in South Carolina and introduce our new products to the market." ... [Read the full article here.]( ----- No. 3 STSS Potential Catalyst - With Manufacturing Ramping Up, Revenue Should Be Getting Even Closer Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products Company now transitions from a pre-revenue research & development start-up to a revenue generating manufacturing company Shipments to commence by the end of the year to support the recently announced distribution and sales agreement with Nephron Pharmaceuticals and its European customers NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply. ... Robert Hayes, Sharps Technology CEO commented: “This is a transformative point for our company as we move from a pre-revenue research & development start-up to a true manufacturing company that should generate revenue in the first half of 2023. Today’s healthcare providers are responsible for managing their supply chains and driving down their total cost of ownership (TCO) for medical treatments. Sharps Technology will be able to offer products that can directly support those programs. At Sharps Technology, we feel that by using better drug delivery technology, we can help create additional medical treatments at no additional cost for patients that need them." "We look forward to a bright future at Sharps Technology," concluded Mr. Hayes. "The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The ability to pull forward our sales plan for customers in the US will create a unique opp. for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023, with additional products to be added to the distribution network by mid-year of 2023." ... [Read the full article here.]( ----- No. 4 STSS Potential Catalyst - New Distro Agreement Signed, 2023 Continues To Look Brighter And Brighter Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in the first half of the year Strengthens the collaboration between Sharps and Nephron to advance the previously announced Inject-EZ startup in South Carolina in early 2023 NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration. “This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals," commented Robert Hayes, Sharps Technology CEO. "The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.” ... [Read the full article here.]( ----- No. 5 STSS Potential Catalyst - Joining The Nasdaq Capital Market In 2022 Opened Sharps To All Kinds Of New Exposure Sharps Technology, Inc. Announces Closing of $16Mn Initial Public Offering NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, today announced the closing of its initial public offering of 3.750Mn units at a public offering price of $4.25 per unit. ... The common st-ock and warrants began trading on The Nasdaq Capital Market on April 14, 2022, under the symbols “STSS” and “STSSW,” respectively. [Read the full article here.]( ----- STSS Recap - Multiple Potential Catalysts Could Spark This Nasdaq Idea Near Term No. 1 - A Low Float Could Provide Significant Potential For Explosive Volatility No. 2 - 2023 Could Be A HUGE Year For Sharps (New Product Launch Nears) No. 3 - With Manufacturing Ramping Up, Revenue Should Be Getting Even Closer No. 4 - New Distro Agreement Signed, 2023 Continues To Look Brighter And Brighter No. 5 - Joining The Nasdaq Capital Market In 2022 Opened Sharps To All Kinds Of New Exposure ----- Coverage is officially reinitiated on STSS. When time permits, do this: Get STSS on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 1/11/23 and ending on 1/13/23 to publicly disseminate information about (STSS) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (STSS). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, FierceInvestor (FI) has been hired for a period beginning on 1/31/23 and ending on 2/1/23 to publicly disseminate information about (STSS) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (STSS). To date, we have now been compensated a total of fifty-two thousand five hundred USD via bank wire transfer to disseminate information about (STSS). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 01/11/2023 and ending on 01/13/2023 to publicly disseminate information about (STSS:US) via digital communications. We have been paid twenty seven thousand five hundred dollars USD via bank wire transfer. We own zero shares of (STSS:US). [( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net